Uni-Bio Science Group Limited, Chinese healthcare company, informed that HeungKong Great Health Fund I, led by the famed Mainland China-based corporation HeungKong Group, has invested HK$120 million in the Group and become its strategic shareholder. Uni-Bio Science and HeungKong Group also forged a strategic alliance, with the Group given access to the medical network of HeungKong Group to distribute its pharmaceutical products, and joint efforts will be made to evaluate the opportunities of setting up biopharmaceutical incubation centers and explore international M&A projects.
Mr. Kingsley LEUNG, Chairman and Executive Director of Uni-Bio Science, said, “The cooperation with HeungKong Group marks an important milestone in the Group’s development. We are very encouraged by HeungKong Group’s decision to invest in Uni-Bio Science because that represents their firm recognition of our business directions and prospects. We believe combining HeungKong Group’s capital strength, medical network and investment banking experience with our professionalism and vision in the biopharmaceutical and related areas will see us make brilliant achievements and reap tremendous synergies, which can effectively enhance both parties’ leading presence in the health and pharmaceutical industries.”
Mr. Sam Lau, Deputy Chairman of HeungKong Group and Chairman of HeungKong Financial Group Limited, said, “Uni-Bio Science’s strengths in biopharmaceutics and biotechnology and its international perspective are what attracted HeungKong Group and the fund founded by Futec International Group to invest in and join hands with it to tap the international pharmaceutical industry”
Partnering with quality companies to expand business has been a major corporate development strategy of Uni-Bio Science. This time, the Group will work with HeungKong Group on three major strategic areas, which are fostering expansion of the Group’s distribution platform, enhancing innovation and pursuing overseas M&A, that fully agree with the Group’s business development approach.
The two partners will look into opportunities of setting up biopharmaceutical incubation centers. With “external innovation” becoming a mainstream strategy in the global pharmaceutical industry, Uni-Bio Science intends to be the first in China to adopt the “external innovation” strategy, that is to work with external start-ups on new project incubation, to speed up new product development. Drawing from HeungKong Group’s successful experience in building an A.I. incubation platform with Microsoft in Nansha, Guangzhou, and the Group’s own R&D capability and pharmaceutical expertise, this innovative strategy stands well to be realized.